Clinical Trial Results:
Coagulopathy during surgery for the repair of Extent 4 Thoraco-Abdominal Aortic Aneurysms - feasibility study of the use of Fibrinogen Concentrate by infusion in place of Fresh Frozen Plasma.
Summary
|
|
EudraCT number |
2009-016709-41 |
Trial protocol |
GB |
Global end of trial date |
31 Dec 2014
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
19 Aug 2021
|
First version publication date |
19 Aug 2021
|
Other versions |
|
Summary report(s) |
Journal |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
FIB692
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
NCT00994045 | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
ACCORD (University of Edinburgh and NHS Lothian)
|
||
Sponsor organisation address |
47 Little France Crescent, Edinburgh, United Kingdom, EH16 4TJ
|
||
Public contact |
Dr Alastair Nimmo, NHS Lothian, +44 0131 242 3224, a.nimmo@ed.ac.uk
|
||
Scientific contact |
Dr Alastair Nimmo, NHS Lothian, +44 0131 242 3224, a.nimmo@ed.ac.uk
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
01 Jul 2017
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
30 Aug 2013
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
31 Dec 2014
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To assess the pattern of coagulation abnormalities in both groups (fibrinogen group and Fresh Frozen Plasma group).
|
||
Protection of trial subjects |
This single-centre study was approved by a research ethics committee, and clinical trial authorisation was granted by the Medicines and Healthcare products Regulatory Agency (MHRA). Written informed consent was obtained from all participants.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
01 Jun 2010
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
No
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
United Kingdom: 20
|
||
Worldwide total number of subjects |
20
|
||
EEA total number of subjects |
20
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
3
|
||
From 65 to 84 years |
17
|
||
85 years and over |
0
|
|
||||||||||
Recruitment
|
||||||||||
Recruitment details |
Between June 2010 and August 2013, twenty-three patients were assessed for enrolment in the study of whom 20 completed the study (10 in each group). Three patients were excluded: taking warfarin (n = 1); declined to participate (n = 1); research staff unavailable (n = 1). | |||||||||
Pre-assignment
|
||||||||||
Screening details |
This was a small, single site pilot study. The study did not require the collection of information about patients screened for eligibility. | |||||||||
Period 1
|
||||||||||
Period 1 title |
Baseline (overall trial) (overall period)
|
|||||||||
Is this the baseline period? |
Yes | |||||||||
Allocation method |
Randomised - controlled
|
|||||||||
Blinding used |
Single blind | |||||||||
Roles blinded |
Subject | |||||||||
Arms
|
||||||||||
Are arms mutually exclusive |
Yes
|
|||||||||
Arm title
|
Fresh frozen plasma (FFP) | |||||||||
Arm description |
- | |||||||||
Arm type |
Active comparator | |||||||||
Investigational medicinal product name |
Fresh Frozen Plasma (FFP)
|
|||||||||
Investigational medicinal product code |
||||||||||
Other name |
||||||||||
Pharmaceutical forms |
Solution for infusion
|
|||||||||
Routes of administration |
Intravenous use
|
|||||||||
Dosage and administration details |
The FFP group received FFP at an initial rate of 15 ml.kg-1.h-1 (approximately 40 mg.kg-1.h-1 of fibrinogen).
|
|||||||||
Arm title
|
Fibrinogen concentrate | |||||||||
Arm description |
Fibrinogen concentrate is derived from pooled human plasma which is purified, treated to inactivate pathogens and freeze dried. It may be stored at room temperature in the operating room and then dissolved in sterile water when required. | |||||||||
Arm type |
Active comparator | |||||||||
Investigational medicinal product name |
Fibrinogen concentrate
|
|||||||||
Investigational medicinal product code |
BT524
|
|||||||||
Other name |
||||||||||
Pharmaceutical forms |
Powder and solvent for solution for infusion
|
|||||||||
Routes of administration |
Intravenous use
|
|||||||||
Dosage and administration details |
Fibrinogen concentrate at 40 mg.kg-1.h-1. Infusion rates were doubled, left unchanged or halved according to subsequent FIBTEM results. The infusions were stopped if FIBTEM A10 was ≥ 8 mm and there was no significant ongoing bleeding.
|
|||||||||
|
|
||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
||||||||||||||||||||||||||||||||||
Reporting group title |
Baseline (overall trial)
|
|||||||||||||||||||||||||||||||||
Reporting group description |
- | |||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Fresh frozen plasma (FFP)
|
||
Reporting group description |
- | ||
Reporting group title |
Fibrinogen concentrate
|
||
Reporting group description |
Fibrinogen concentrate is derived from pooled human plasma which is purified, treated to inactivate pathogens and freeze dried. It may be stored at room temperature in the operating room and then dissolved in sterile water when required. |
|
|||||||||||||
End point title |
Allogeneic blood components | ||||||||||||
End point description |
|||||||||||||
End point type |
Primary
|
||||||||||||
End point timeframe |
During surgery and up to 24 h postoperatively.
|
||||||||||||
|
|||||||||||||
Statistical analysis title |
Allogeneic blood components | ||||||||||||
Comparison groups |
Fibrinogen concentrate v Fresh frozen plasma (FFP)
|
||||||||||||
Number of subjects included in analysis |
20
|
||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||
Analysis type |
|||||||||||||
P-value |
= 0.011 | ||||||||||||
Method |
Wilcoxon (Mann-Whitney) | ||||||||||||
Confidence interval |
|
|||
Adverse events information [1]
|
|||
Timeframe for reporting adverse events |
Randomisation to 24 hours post surgery.
|
||
Assessment type |
Systematic | ||
Dictionary used for adverse event reporting
|
|||
Dictionary name |
Not applicable | ||
Dictionary version |
0
|
||
Frequency threshold for reporting non-serious adverse events: 0% | |||
Notes [1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported. Justification: There were no adverse events including non-serious adverse events. |
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? Yes | |||
Date |
Amendment |
||
11 Mar 2010 |
Increase in volume of blood taken from each patient to allow all the necessary clotting tests to be performed. Blood taken at each sampling point will increase from 15mls to 22.5mls and max total will increase from 180mls to 270 mls.
Modification of pharmacy label that will be applied to study drug. Drug label now states that drug must be stored at below 25 degrees & do not freeze. |
||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported | |||
Online references |
|||
http://www.ncbi.nlm.nih.gov/pubmed/30467829 |